PALAU PHARMA S.A.
PALAU PHARMA is a newly created biopharmaceutical company, whose mission is the discovery and development of drug candidates for the treatment of chronic inflammatory conditions. The company is a spin-out from GRUPO URIACH’s R&D Department, and so it benefits from the advantage of its integration in a well established Group which has been in the pharmaceutical business for over 160 years, and which is leading Spanish pharmaceutical company when it comes to R&D productivity.
PALAU PHARMA S.A.
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2006-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Status:
Active
Contact:
+34 93 864 96 92
Total Funding:
0
Investors List
Najeti Capital
Najeti Capital investment in Private Equity Round - Palau Pharma S.A.
More informations about "Palau Pharma S.A."
Palau Pharma S.A. - Ownership and Business Overview | Mergr
Pol. Ind. Riera de Caldes Avinguda Camí Reial 51-57 Palau-solità i Plegamans, Barcelona, 08184 Spain , +34 93 864 96 92See details»
Palau Pharma | Pharmaceutical - The Pharmaletter
Palau Pharma, S.A. is the spin out of the R&D division in the Uriach Group. Its product portfolio is made up of 10 projects in various stages of development, ranging from the discovery of the active ingredient to the final clinical stages. …See details»
Palau Pharma SA - Drug pipelines, Patents, Clinical trials - Synapse
Nov 1, 2024 Explore Palau Pharma SA with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 1 news, and 5 literature, Disease Domain:Immune System Diseases, …See details»
Palau Pharma SA - Plegamans, Spain - bionity.com
Palau Pharma is a product-driven biopharmaceutical company focused on the discovery and development of innovative, improved and safer medicines for the treatment of diseases with …See details»
Palau Pharma - LinkedIn
Palau Pharma is a product-driven biopharmaceutical company focused on the discovery and development of innovative, improved and safer medicines for the treatment of diseases with …See details»
Palau Pharma | VentureRadar
Palau Pharma (Barcelona, Spain) is a newly created Spanish biopharmaceutical company devoted to the discovery and development of drug candidates for the treatment of …See details»
Palau Pharma S.A. - CoBee Company Profile & Funding Rounds
PALAU PHARMA is a newly created biopharmaceutical company, whose mission is the discovery and development of drug candidates for the treatment of chronic inflammatory conditions. The …See details»
Organization | Palau Pharma S.A.
Palau Pharma S.A. Report issue For profit Phase 2 Founded: Barcelona Spain (2006)See details»
Organization | Palau Pharma S.A. - cdek.pharmacy.purdue.edu
Palau Pharma S.A. Report issue For profit Phase 2 Founded: Barcelona Spain (2006)See details»
Palau Pharma Company Profile - YouTube
Barcelona based Palau Pharma Company Profile was created in 2010 by PharmaTelevision.Palau Pharma S.A. ("Palau") is a product-driven biopharmaceutical compan...See details»
Palau Pharma SA (Palau Pharma SA) - 药物管线_专利_临床试验_投 …
了解Palau Pharma SA (Palau Pharma SA)公司的药物管线，治疗领域，技术平台，以及它的4项临床试验, 1篇新闻和5篇文献，疾病领域:神经系统疾病，免疫系统疾病，技术平台:小分子化 …See details»
Palau Pharma SA - Company Profile and News - Bloomberg Markets
Company profile page for Palau Pharma SA including stock price, company news, executives, board members, and contact informationSee details»
Palau Pharma S.A. - Crunchbase
PALAU PHARMA is a newly created biopharmaceutical company, whose mission is the discovery and development of drug candidates.See details»
Palau Pharma S.A. - Funding, Financials, Valuation & Investors
Oct 1, 2013 How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number ... Money Raised . Lead Investors . Oct 1, 2013: Private Equity …See details»
Pain Therapeutics (Almirall/Esteve/Palau Pharma/Proteomika)
Pain Therapeutics (Almirall/Esteve/Palau Pharma/Proteomika), Initially developed by Esteve Pharmaceuticals S.A., Now, its global highest R&D status is Pending, Therapeutic Areas: …See details»
UR-13870 - Drug Targets, Indications, Patents - Synapse - Patsnap
UR-13870: a p38α inhibitors Drug, Initially developed by Palau Pharma SA, Now, its global highest R&D status is Preclinical, Mechanism: p38α inhibitors(P38 α mitogen-activated protein …See details»
Palau Pharma, S.A Company Profile- Outlook, Business Segments ...
'Palau Pharma, S.A Company Profile' is a complete analysis of the company's operations, strategies, outlook and historic performance. The research work analyzes key strategies in …See details»
Seliforant - Drug Targets, Indications, Patents - Synapse
Sensorion has been listed on the Euronext Growth Paris exchange since April 2015. www.sensorion-pharma.com Contacts Sensorion Nawal OuzrenCEO contact@sensorion …See details»
Albaconazole - Drug Targets, Indications, Patents - Synapse
Thirty-one novel albaconazole derivatives were designed and synthesized based on our previous work. All compounds exhibited potent in vitro antifungal activities against seven pathogenic …See details»